GGrantIndex
← Leaderboards

Steven C Ghivizzani

Brigham And Women'S Hospital

$7,278,988
Attributed
$7,278,988
Total exposure
6
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.5M · FY200514
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14

Funding mix

By agency

NIH$7,278,988 · 6

By mechanism

R01$6,852,700 · 3
R03$254,250 · 1
R41$142,038 · 1
R13$30,000 · 1

Top collaborators

No co-investigators on record.

Most similar at Brigham And Women'S Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Gene Therapy

Research focus

Gene TherapyArthritisJointsGenesGene Delivery SystemClinical ApplicationGene ExpressionBiologicalGene DeliveryDesignVectorRheumatoid ArthritisMediatingAffectTransgenic OrganismsResearch StudyBasePhenotypeGene TransferTransfection /Expression VectorBiotechnologyTissue /Cell CultureKneeLaboratory Rabbit

Grant awards (28)

Delivery of Soluble FGFR3 as a Treatment for Achondroplasia$310,111
R01 · FY2014 · AR · contact PI
Delivery of Soluble FGFR3 as a Treatment for Achondroplasia$300,618
R01 · FY2013 · AR · contact PI
Utility of AAV serotypes for gene delivery in treatment of chronic joint disease$292,252
R01 · FY2013 · AR · contact PI
Delivery of Soluble FGFR3 as a Treatment for Achondroplasia$316,440
R01 · FY2012 · AR · contact PI
Utility of AAV serotypes for gene delivery in treatment of chronic joint disease$308,370
R01 · FY2012 · AR · contact PI
Utility of AAV Serotypes for Gene Delivery in Treatment of Chronic Joint Disease$862,998
R01 · FY2011 · AR · contact PI
Delivery of Soluble FGFR3 as a Treatment for Achondroplasia$316,440
R01 · FY2011 · AR · contact PI
Utility of AAV serotypes for gene delivery in treatment of chronic joint disease$309,009
R01 · FY2011 · AR · contact PI
Delivery of Soluble FGFR3 as a Treatment for Achondroplasia$329,625
R01 · FY2010 · AR · contact PI
Utility of AAV serotypes for gene delivery in treatment of chronic joint disease$322,465
R01 · FY2010 · AR · contact PI
Utility of AAV serotypes for gene delivery in treatment of chronic joint disease$326,231
R01 · FY2009 · AR · contact PI
5th international meeting of gene and cell therapies for arthritis and related di$20,000
R13 · FY2008 · AR · contact PI
Gene Delivery to Cartilage Defects via Marrow Coagulates$298,339
R01 · FY2007 · AR · contact PI
5th international meeting of gene and cell therapies for arthritis and related di$10,000
R13 · FY2007 · AR · contact PI
Gene Delivery to Cartilage Defects via Marrow Coagulates$307,249
R01 · FY2006 · AR · contact PI
Persistence of Transgene Expression in Synovium$262,139
R01 · FY2006 · AR · contact PI
Gene Delivery to Cartilage Defects via Marrow Coagulates$341,925
R01 · FY2005 · AR
Persistence of Transgene Expression in Synovium$307,733
R01 · FY2005 · AR
Gene Delivery to Cartilage Defects via Marrow Coagulates$330,716
R01 · FY2004 · AR
Persistence of Transgene Expression in Synovium$292,718
R01 · FY2004 · AR
Persistence of Transgene Expression in Synovium$236,242
R01 · FY2003 · AR
Gene Delivery to Cartilage Defects via Marrow Coagulates$189,426
R01 · FY2003 · AR
Gene Delivery to Cartilage Defects via Marrow Coagulates$182,610
R01 · FY2003 · AR
Gene Therapy for Arthritis Using Lentiviral Vectors$142,038
R41 · FY2003 · AR
Persistence of Transgene Expression in Synovium$109,044
R01 · FY2003 · AR
Intra-articular Gene Transfer and Expression of sCD4$84,750
R03 · FY2003 · AR
Intra-articular Gene Transfer and Expression of sCD4$84,750
R03 · FY2002 · AR
Intra-articular Gene Transfer and Expression of sCD4$84,750
R03 · FY2001 · AR